Ring Therapeutics Enters into Partnerships with A*STAR and SERI to Boost Gene Therapy Research in Singapore
Tuesday, November 05, 2024
Ring Therapeutics has announced strategic partnerships with Agency for Science, Technology, and Research (A*STAR) and the Singapore Eye Research Institute (SERI).
These collaborations aim to enhance research and development (R&D) efforts and strengthen the biomedical science ecosystem in the region.
The partnerships will support various aspects of Ring Therapeutics' platform, including early discovery initiatives focused on characterising new anellovirus genomes for use in ophthalmology and oncology.
Additionally, the collaborations will help expand the company's indication portfolio by testing innovative payloads across different therapeutic areas and improving the performance of its next-generation manufacturing processes.
A*STAR and SERI will work together to accelerate the development of new treatments for eye diseases and cancer while enhancing production methods and technologies.
This collaboration aims to leverage their combined expertise in manufacturing and scientific advancements within Singapore's biotech sector.
The partnership is expected to lead to significant advancements in gene therapy, offering new treatment options for previously difficult-to-treat ophthalmic conditions and potentially improving patient outcomes in oncology.
Source: ringtx.com
